1
|
Ishido H, Tajima H, Meguro S, Takada M, Tatsuoka T, Kawasaki K, Ono Y, Ban S, Okuyama T, Yoshitomi H. Primary anastomosing hemangioma as a preoperative diagnostic mimicker of retroperitoneal cavernous hemangioma: A case report. Oncol Lett 2024; 27:254. [PMID: 38646490 PMCID: PMC11027107 DOI: 10.3892/ol.2024.14386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 01/30/2024] [Indexed: 04/23/2024] Open
Abstract
Anastomosing hemangioma (AH) is rare and a newly recognized variant of capillary hemangioma that is mostly found in the genitourinary tract. Additionally, AH is sometimes difficult to diagnose without pathological specimens. It is difficult to diagnose preoperatively due to the lack of specific clinical and radiologic appearance. The present report describes the imaging features from a radiological perspective and outlines the clinicopathologic features and treatment options. A 67-year-old woman was referred to Dokkyo Medical University Saitama Medical Center (Koshigaya, Japan) for a retroperitoneal tumor that was identified at a medical checkup 4 years prior. The patient had no symptoms, no abnormal physical signs and no past medical or specific family history. Routine blood tests were all within the normal ranges. A nonenhanced CT scan showed a circular, homogenous, well-circumscribed retroperitoneal tumor that was ~32×23 mm in size, between the abdominal aorta and the inferior vena cava, and just below the left renal vein. On a contrast-enhanced multidetector CT scan, the tumor showed heterogeneous septal enhancement in the arterial phase and persistent enhancement in the portal phase. The tumor was diagnosed as a benign neurogenic tumor or a retroperitoneal cavernous hemangioma at the time, and the patient was intended to be followed up at the outpatient clinic. However, it gradually increased to a maximum diameter of 35 mm over 4 years. Finally, it was completely resected by open laparotomy and pathologically diagnosed as AH. Retroperitoneal hemangioma is extremely rare in adulthood and has been confirmed in only 1-3% of all retroperitoneal tumors. To the best of our knowledge, only 6 cases of para-aortic AH have been reported. The incidence of this variant is very low. However, AH may be included in the differential diagnosis when a slowly progressing heterogeneous mass appears in the para-aortic region that exhibits a CT-enhanced pattern similar to a typical cavernous hemangioma.
Collapse
Affiliation(s)
- Hirotaka Ishido
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Hidehiro Tajima
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Soya Meguro
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Musashi Takada
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Teppei Tatsuoka
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Keishi Kawasaki
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Yuko Ono
- Department of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan
- Department of Diagnostic Pathology, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan
| | - Shinichi Ban
- Department of Pathology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Takashi Okuyama
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| | - Hideyuki Yoshitomi
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama 343-8555, Japan
| |
Collapse
|
2
|
Kobori I, Noro T, Takada M, Soga K, Tamano M, Yoshitomi H, Yamanouchi E. Recanalization by magnetic compression anastomosis for complete bile duct obstruction and retrieval of a migrated magnet. Endoscopy 2023; 55:E993-E995. [PMID: 37604434 PMCID: PMC10442207 DOI: 10.1055/a-2134-7324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/23/2023]
Affiliation(s)
- Ikuhiro Kobori
- Department of Gastroenterology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - Takuji Noro
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - Musashi Takada
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - Koichi Soga
- Department of Gastroenterology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - Masaya Tamano
- Department of Gastroenterology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - Hideyuki Yoshitomi
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
| | - Eigoro Yamanouchi
- Department of Radiology, International University of Health and Welfare Hospital, Tochigi, Japan
| |
Collapse
|
3
|
Noro T, Tatsuoka T, Takada M, Meguro S, Ishido H, Kawasaki K, Mitsui T, Takeshita E, Sato T, Ban S, Tajima H, Okuyama T, Yoshitomi H. Primary hepatic neuroendocrine neoplasm presenting as a massive cystic liver tumor mimicking mucinous cystic neoplasm of the liver: A case report and literature review. Oncol Lett 2023; 26:304. [PMID: 37323819 PMCID: PMC10265362 DOI: 10.3892/ol.2023.13890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Accepted: 04/17/2023] [Indexed: 06/17/2023] Open
Abstract
Neuroendocrine neoplasms (NENs) preferentially arise in the bronchopulmonary tree or the gastrointestinal tract. Notably, primary hepatic NENs are extremely rare. The present study describes a case of hepatic NEN presenting as a giant hepatic cystic lesion. A 42-year-old woman presented with a large liver tumor. Contrast-enhanced abdominal computed tomography revealed a cystic tumor (18 cm) in their left liver. The tumor exhibited liquid components and mural solid nodules with enhanced effects. The lesion was diagnosed as mucinous cystic carcinoma (MCC) preoperatively. The patient underwent a left hepatectomy, and the postoperative course was uneventful. The patient has been alive without recurrence for 36 months postoperatively. The pathological diagnosis was NEN G2. This patient had ectopic pancreatic tissue in the liver and thus the ectopic pancreatic origin of the tumor was suspected. The present study describes a case of resected cystic primary NEN of the liver that was difficult to differentiate from mucinous cystic neoplasms. As primary liver NENs are extremely rare, further studies are needed to establish their diagnosis and treatment.
Collapse
Affiliation(s)
- Takuji Noro
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Teppei Tatsuoka
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Musashi Takada
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Souya Meguro
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Hirotaka Ishido
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Keishi Kawasaki
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Takashi Mitsui
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Emiko Takeshita
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Taiki Sato
- Department of Pathology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Sinichi Ban
- Department of Pathology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Hidehiro Tajima
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Takashi Okuyama
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| | - Hideyuki Yoshitomi
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, 343-8555, Japan
| |
Collapse
|
4
|
Kinoshita K, Otsuka R, Takada M, Tsukamoto-Yasui M, Nishita Y, Tange C, Tomida M, Jinzu H, Shimokata H, Kuzuya M, Imaizumi A, Arai H. Low Amino Acid Score of Breakfast is Associated with the Incidence of Cognitive Impairment in Older Japanese Adults: A Community-Based Longitudinal Study. J Prev Alzheimers Dis 2022; 9:151-157. [PMID: 35098986 DOI: 10.14283/jpad.2021.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The protein digestibility-corrected amino acid score (PDCAAS) represents the degree of utilizable dietary protein, namely the protein quality. The PDCAAS of a diet is required to be evaluated on a meal-by-meal basis, as food digestion and absorption occur with each meal intake. Although a positive association between protein intake and cognitive function has been reported, no study has investigated the association between PDCAAS of a diet and cognitive function. OBJECTIVES To investigate the relationship between PDCAAS of a diet and cognitive impairment in older adults. DESIGN Longitudinal epidemiological study. SETTING Community-based setting. PARTICIPANTS We analyzed 541 community-dwellers who participated in both baseline and follow-up survey. They were 60-83 years of age without cognitive impairment at baseline. MEASUREMENTS Cognitive impairment was defined as a Mini-Mental State Examination (MMSE) score ≤27. Individual PDCAASs were calculated for each of three regular meals from the 3-day dietary records at baseline. Participants were classified into two groups according to the sex-specific tertiles (T1-T3) of the PDCAAS for each meal (i.e., T1 as the low score group and T2-T3 as the medium and high score group). The dependent variable was cognitive impairment observed after 4 years, and the explanatory variables were the PDCAAS groups for each meal (the medium and high group as the reference) and covariates (sex, age, body mass index, education, depressive symptoms, medical history, protein intake at each meal, and the MMSE score at baseline). Multivariable logistic regression analysis was performed to evaluate the low PDCAAS group for cognitive impairment after 4 years. RESULTS A significant association was observed only between a low PDCAAS of breakfast and the incidence of cognitive impairment (the adjusted odds ratios [95% confidence intervals] of low PDCAAS for cognitive impairment for breakfast, lunch, and dinner were 1.58 [1.00-2.50], 0.85 [0.54-1.34], and 1.08 [0.71-1.65], respectively). CONCLUSION A lower PDCAAS of breakfast, i.e., a diet with poor quality of protein, was associated with the incidence of cognitive impairment in older adults of the community.
Collapse
Affiliation(s)
- K Kinoshita
- Rei Otsuka, Section of NILS-LSA, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430 Morioka, Obu, Aichi 474-8511, Japan, E-mail: ; Tel: +81-562-46-2311; Fax: +81-562-48-2373
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Sugamata N, Okuyama T, Takeshita E, Oi H, Hakozaki Y, Miyazaki S, Takada M, Mitsui T, Noro T, Yoshitomi H, Oya M. Surgical site infection after laparoscopic resection of colorectal cancer is associated with compromised long-term oncological outcome. World J Surg Oncol 2022; 20:111. [PMID: 35387666 PMCID: PMC8988355 DOI: 10.1186/s12957-022-02578-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2022] [Accepted: 03/18/2022] [Indexed: 11/10/2022] Open
Abstract
Background We evaluated the influence of infectious complications, particularly surgical site infection (SSI), on long-term oncological results after elective laparoscopic resection of colorectal cancer. Methods A total of 199 patients who underwent laparoscopic elective resection with negative resection margins for stage I–III colorectal cancer were retrospectively examined. The postoperative course was recorded based on hospital records, and cancer relapse was diagnosed based on radiological or pathological findings under a standardized follow-up program. The severity of complications was graded using Clavien-Dindo (CD) classification. Results SSI was found in 25 patients (12.6%), with 12 (6.0%) showing anastomotic leak. The postoperative relapse-free survival (RFS) rate was significantly lower in patients with SSI (49.2%) than in patients without SSI (87.2%, P<0.001). Differences in RFS were found after both colectomy and rectal resection (P<0.001 and P<0.001, respectively). RFS did not differ between patients who had major SSI CD (grade III) and those who had minor SSI CD (grades I or II). Multivariate Cox regression analysis identified the occurrence of SSI and pathological stage as independent co-factors for RFS (P<0.001 and P=0.003). Conclusion These results suggest that postoperative SSI compromises long-term oncological results after laparoscopic colorectal resection. Further improvements in surgical technique and refinements in perioperative care may improve long-term oncological results.
Collapse
Affiliation(s)
- Nana Sugamata
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Takashi Okuyama
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan.
| | - Emiko Takeshita
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Haruka Oi
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Yuhei Hakozaki
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Shunya Miyazaki
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Musashi Takada
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Takashi Mitsui
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Takuji Noro
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Hideyuki Yoshitomi
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Masatoshi Oya
- Department of Surgery, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| |
Collapse
|
6
|
Kawaguchi K, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga R, Tamura N, Aruga T, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Toi M. 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
7
|
Kinoshita K, Otsuka R, Takada M, Tsukamoto-Yasui M, Nishita Y, Tange C, Tomida M, Shimokata H, Kuzuya M, Imaizumi A, Arai H. The Association between Dietary Amino Acid Intake and Cognitive Decline 8 Years Later in Japanese Community-Dwelling Older Adults. J Nutr Health Aging 2021; 25:165-171. [PMID: 33491030 DOI: 10.1007/s12603-020-1470-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVES Previous studies have reported a relationship between low protein intake and cognitive decline and have suggested that this association may be related to specific amino acid intake. However, the effects of amino acid intake on the maintenance of cognitive function have yet to be clarified. We examined the longitudinal association between dietary amino acid intake and cognitive function in community-dwelling older adults. DESIGN Longitudinal epidemiological study. SETTING Community-based setting. PARTICIPANTS This study comprised 427 study participants aged 60-82 years with no cognitive decline, defined as a Mini-Mental State Examination (MMSE) score of >27 at baseline, who also participated in a follow-up. The average and standard deviation of the follow-up period was 8.2 ± 0.3 years. MEASUREMENTS Dietary intake was assessed using three-day dietary records at baseline. Participants were classified into quartiles (Q1-Q4) based on the intake of 19 amino acids for males and females. Next, we classified participants into Q1 and Q2-Q4 groups. Cognitive function was assessed using the MMSE both at baseline and at follow-up. Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between the Q1 group and cognitive decline (MMSE ≤27), using the Q2-Q4 group as a reference group. Covariates were age, sex, body mass index, years of education, severity of depressive symptoms, history of lifestyle diseases (hypertension, dyslipidemia, diabetes mellitus, stroke, and ischemic heart disease), energy intake (kcal/d), protein intake (g/d), and MMSE score at baseline. RESULTS Cognitive decline was present in 133 (31.1%) participants. After adjustment for covariates, including total protein intake, the ORs (95% CIs) for cognitive decline were 2.40 (1.21-4.75) for lysine, 2.05 (1.02-4.09) for phenylalanine, 2.18 (1.09-4.34) for threonine, and 2.10 (1.06-4.15) for alanine. CONCLUSION The results suggest that lysine, phenylalanine, threonine, and alanine intake is important for the maintenance of cognitive function in older people, independent of total protein intake.
Collapse
Affiliation(s)
- K Kinoshita
- Rei Otsuka, Section of NILS-LSA, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430 Morioka, Obu, Aichi 474-8511, Japan, Tel: +81-562-46-2311; FAX: +81-562-46-2373; E-mail:
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Takahashi S, Mine T, Kawai H, Takai K, Yoshikawa F, Takada M, Fujita K, Nishibori Y, Maruyama T. Conduction gaps after pulmonary vein isolation due to high contact force ablation in patients with atrial fibrillation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Catheter ablation for atrial fibrillation (AF) with high contact force (CF) has been reported to lead to the gaps after pulmonary vein isolation (PVI), and the appearance of the gaps depends on the site in the left atrium (LA).
Purpose
The aim of this study is to clarify the relationship between the gaps appearance and high CF.
Methods
In the clinical study, 74 consecutive patients (39 males, age 71±9, 46 with paroxysmal AF) underwent conventional PVI with a point-by-point radiofrequency (RF) ablation using a CF sensing catheter (TactiCath SETM). RF energy (J), number of RF point, Lesion index (LSI), force-time integral (FTI), average CF (g), and the degree of LA depression with high CF were evaluated. In the experimental study (figure), the relationship between the ablation area and the degree of depression with high CF using bovine left ventricular wall.
Results
In the clinical study, the gaps were found in 175 of 1182 sites after first path PVI ablation. The CF in the gap sites was higher than without the gap sites in RPV roof, anterior RSPV and anterior RPV carina (18.9±6.8 vs 15.0±5.7g p=0.0262, 26.4±11.6 vs 19.5±6.0g p=0.0029, 22.7±6.4 vs 19.1±5.5g, p=0.0161). Meanwhile, there were no differences in RF energy, number of RF point, LSI, FTI. High CF (≥30g) showed a depression of 3 mm or more in only RPV roof and anterior RPV (figure). In the experimental study, the ablation range narrowed as the indentation deepened with more than 30g CF (r=0.6417, p=0.0625).
Conclusion
Catheter ablation for AF with high contact force might lead to the gaps in RPV roof and anterior RPV site by the reduction of the ablation area due to depression caused by the pressure.
Extension of each contact force
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - T Mine
- Hyogo College of Medicine, cardiovascular division, Hyogo, Japan
| | - H Kawai
- Kawasaki Hospital, Kobe, Japan
| | - K Takai
- Kawasaki Hospital, Kobe, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Kang Y, Kikawa Y, Kotake T, Tsuyuki S, Takahara S, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. 52P Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
10
|
Miura H, Takada M, Fujiwara M, Fujiwara S. Topical imiquimod monotherapy for a recurrent lesion of Merkel cell carcinoma. Br J Dermatol 2020; 184:e30. [PMID: 32845515 DOI: 10.1111/bjd.19402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 07/01/2020] [Accepted: 07/01/2020] [Indexed: 11/27/2022]
Affiliation(s)
- H Miura
- Department of Dermatology, Osaka Minato Central Hospital, Osaka, Japan
| | - M Takada
- Department of Dermatology, Osaka Minato Central Hospital, Osaka, Japan
| | - M Fujiwara
- Department of Dermatology, Osaka Minato Central Hospital, Osaka, Japan
| | - S Fujiwara
- Department of Dermatology, Osaka Minato Central Hospital, Osaka, Japan
| |
Collapse
|
11
|
Suzuki M, Inoue K, Nakagawa H, Isa T, Takada M, Nishimura Y. Deep brain stimulation of the ventral midbrain facilitates the output to forelimb muscles via the primary motor cortex in monkeys. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
12
|
Takada M, Okuyama T, Yoshioka R, Noie T, Takeshita E, Sameshima S, Oya M. A case with mesenteric desmoid tumor after laparoscopic resection of stage I sigmoid colon cancer. Surg Case Rep 2019; 5:38. [PMID: 30820780 PMCID: PMC6395456 DOI: 10.1186/s40792-019-0587-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2018] [Accepted: 02/10/2019] [Indexed: 12/11/2022] Open
Abstract
Background Intra-abdominal desmoid tumors are rare and generally occur in some patients with familial adenomatous polyposis or secondary to an external stimulus such as surgical trauma. We report herein a case of intra-abdominal desmoid tumor in the jejunal mesentery after laparoscopic colectomy for sigmoid colon cancer. Case presentation A 74-year-old woman underwent laparoscopic sigmoid colectomy for colon cancer with pathological stage I. Follow-up computed tomography (CT) 18 months after primary surgery showed a nodular and enhanced soft tissue density mass, 20 mm in size, in the mesentery at the left side of the abdomen. Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were within the normal range. Fluorodeoxyglucose positron emission tomography did not suggest cancer recurrence. Another CT scan, done 1 month later, revealed that the tumor had enlarged to 25 mm in size. Although the pathological diagnosis was not obtained, we suspected recurrence of the sigmoid colon cancer and applied chemotherapy using capecitabine, oxaliplatin, and bevacizumab. After 3 cycles of chemotherapy, however, the tumor had enlarged further. Therefore, the surgical resection of the tumor was performed to determine the diagnosis and to achieve possible curative resection of the tumor. The tumor existed in the mesentery of the jejunum, 100 cm from the ligament of Treitz, and showed invasive growth. We resected 40 cm of the jejunal segment together with the tumor. Microscopically, the tumor was composed of fibroblast, myofibroblast, and infiltrating the inflammatory cell and diagnosed as desmoid tumor by immunostaining (desmin+/−, β-catenin+, CD117−, vimentin+). At 33 months after the resection of the desmoid tumor, neither the sigmoid colon cancer nor desmoid tumor has had a recurrence. Conclusions After surgery for gastrointestinal cancer, it is difficult to differentiate between intra-abdominal desmoid tumor and recurrence. The possibility of intra-abdominal desmoid should be considered along with tumor recurrence during postoperative surveillance after resection of gastrointestinal cancer, especially when the risk of recurrence is low.
Collapse
Affiliation(s)
- Musashi Takada
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Takashi Okuyama
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan.
| | - Ryuji Yoshioka
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Tamaki Noie
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Emiko Takeshita
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Shinichi Sameshima
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| | - Masatoshi Oya
- Department of Surgery, Saitama Medical Center, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan
| |
Collapse
|
13
|
Maeshima Y, Takahara S, Yamauchi A, Yamagami K, Sugie T, Yamashiro H, Kato H, Torii M, Takada M, Torii M. Abstract P3-03-21: Usefulness of sentinel lymph node biopsy by indocyanine green fluorescence method for cN0 breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-03-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Indocyanine green (ICG) fluorescence method (ICG-f) has been recently widely used in sentinel lymph node (SLN) detection. The advantages of ICG-f are no radiation exposure, no limitation to use in high-volume medical centers without radioactive facility, and to confirm lymph flow as a real-time image from outside the body. ICG-f identified an average of 2.3-3.4 SLNs and the detection rate was 99%, compared to 1.7-2 SLNs by RI methods. Long-term observation after SNB using ICG-f has not been reported, including arm lymphedema as the complication of this method.We evaluate the usefulness of SLN biopsy (SNB) for cN0 breast cancer patients from data of multicenter cohort study on long-term results after negative SNB by ICG-f.
Methods. Eleven hundred and thirty-two women were enrolled who had histologically proved clinical stage T1-4, pN0, M0 primary invasive breast cancer with SNB using ICG-f (ICG alone or combination of RI/blue dye method) sparing axillary lymph node dissection from May 2007 to December 2015. This study is retrospective, multicenter cohort study conducted at 6 centers in Japan. Primary endpoint is axillary recurrence rate. We analyzed the correlation with the axillary recurrence and adjuvant systemic therapy, adjuvant radiotherapy, and the clinicopathological characteristics. Secondary endpoint is lymphedema.
Results and Discussion. The median follow-up time was 41 (range 21-117) months, and axillary recurrence was found in 6 patients (0.53%). Five out of 6 patients were not received standard adjuvant systemic therapy or adjuvant radiation therapy after breast conserving surgerybecause of patient's preference or old age. Lymphedema was identified only 4 patients in 632 patients. It is reported that axillary recurrence after SNB was 0.3-1.65%, which was consistent with our result. Lymphedema was not frequent in patients received SNB using ICG-f, because SLNs are removed along with lymphatic ducts in the limited area of axillary adipose tissue.
Conclusion.Axillary recurrence after negative SNB using ICG-f was comparable to RI or blue dye method. It might be important to perform appropriate adjuvant medication or radiation therapy for preventing axillary recurrence after SNB using ICG-f.
Next, ICG-f after neoadjuvant chemotherapy is to be investigated, because itis reported that removing more than 2 SLNs were associated with a lower likelihood of false negative ratio in patients with clinically node-positive disease converted to clinically node-negative after chemotherapy, and ICG-f might overcome this issue.
Citation Format: Maeshima Y, Takahara S, Yamauchi A, Yamagami K, Sugie T, Yamashiro H, Kato H, Torii M, Takada M, Torii M. Usefulness of sentinel lymph node biopsy by indocyanine green fluorescence method for cN0 breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-21.
Collapse
Affiliation(s)
- Y Maeshima
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - S Takahara
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - A Yamauchi
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - K Yamagami
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - T Sugie
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - H Yamashiro
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - H Kato
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - M Torii
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - M Takada
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - M Torii
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
14
|
Matsumoto Y, Gu L, Bise R, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Takada M, Kataoka M, Sakurai T, Yagi T, Sato I, Togashi K, Shiina T, Toi M. Abstract P6-01-02: Machine learning-based structural analysis and oxygen saturation measurement of tumor-associated vessels in breast cancer using a photoacoustic tomography system. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Breast cancer induces angiogenesis, one of the primary factors responsible for tumor progression. Therefore, the ability to visualize angiogenesis at a higher resolution is crucial. Photoacoustic tomography is a noninvasive method of visualizing angiogenesis involving light absorption and ultrasonic wave emission. If the irradiation light wavelength is adjusted for hemoglobin, vascular imaging is possible. Furthermore, using two wavelengths for oxidized and reduced hemoglobin, “S-factor,” can be calculated, which nearly corresponds to oxygen saturation. Therefore, photoacoustic imaging allows the assessment of breast lesions from vascular structural and functional viewpoints.
Objectives
This study aimed to demonstrate the possible utility of photoacoustic tomography for clinical application focusing on the morphologic features and oxygen saturation status of breast tumor-related vessels.
Methods
For the morphological analysis, we applied a machine learning-based method for automatic vessel extraction, and for the functional analysis we evaluated hemoglobin oxygen saturation calculating signals obtained at two wavelengths. In our system, a 3D ultrasound image was simultaneously acquired as a volume image of a tumor, which helped analyze the positional relationship between the vessels and the tumor.
Results
On morphological analysis, the fine structure of tumor-related vessels was rendered in high resolution. In our system, the blood vessels branched toward the tumor 2-3 more times more frequently than observed on contrast-enhanced MRI, illustrating a finer level of blood vessels near the tumor on our system than on MRI. Next, we analyzed the six morphologic features of vessels (radius, volume, curvature, contraction, maximum angle and vessel branch number) that are associated with the pathologic condition in neuroscience. We determined that the feature distribution of vessels located close to the tumor differed from that located away from the tumor. For example, vessels near the tumor had higher curvature, which means they are more tortuous than healthy vessels. The difference in the distribution of all six features was statistically significant on the Kolmogorov-Smirnov test.
On functional analysis, S-factor measurement of the healthy human breast demonstrated clearly demarcated arteries and veins. The S-factor of any artery was nearly 100%, while that of the veins inside the breast cancer tended to be a little higher (approximately 5%) compared to that in the healthy part. This tendency of veins was not recognized in benign tumors. This could show arteriovenous shunt in cancer microenvironment. We found low saturation signals emerging in the tumor tissue following bevacizumab-containing chemotherapy, indicating the possibility that our system reveals microenvironment changes.
Discussion
If our system can identify the structure or oxygen saturation characteristics unique to tumor-associated vasculature, it could contribute to the improved accuracy of breast cancer diagnosis and allow the observation of tumor vessel normalization because of the drug treatment. An earlier grasp of the therapeutic effect could lead to the provision of individualized medicine.
Citation Format: Matsumoto Y, Gu L, Bise R, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Takada M, Kataoka M, Sakurai T, Yagi T, Sato I, Togashi K, Shiina T, Toi M. Machine learning-based structural analysis and oxygen saturation measurement of tumor-associated vessels in breast cancer using a photoacoustic tomography system [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-01-02.
Collapse
Affiliation(s)
- Y Matsumoto
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - L Gu
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - R Bise
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - Y Asao
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - H Sekiguchi
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - A Yoshikawa
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - T Ishii
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - M Takada
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - M Kataoka
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - T Sakurai
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - T Yagi
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - I Sato
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - K Togashi
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - T Shiina
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| | - M Toi
- Kyoto University, Kyoto, Japan; National Institute of Informatics, Tokyo, Japan; Kyushu University, Fukuoka, Japan; Japan Science and Technology Agency, Tokyo, Japan
| |
Collapse
|
15
|
Mitsunaga S, Takada M, Nishikawa S, Imaizumi A, Ishii M, Ikeda M. Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Ohtani S, Yasuaki S, Takada M, Ohi Y, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of Neo-Adjuvant Systemic Therapy for Basal HER2 type Breast Cancer – Results from Retrospective Cohort Study of Japan Breast Cancer Research Group (JBCRG) – C03. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30506-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Sakita-Kawaguchi N, Nakayama Y, Okuda T, Nishino H, Seo S, Hatano E, Toi M. Abstract PD2-07: Real-time navigation for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd2-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background)
Sentinel lymph node (SLN) biopsy using indocyanine green fluorescence (fICG) method showed equal or better identification rate compared with blue dye or radioisotope (RI) method. In the fICG method, lymphatic vessels which drain into the SLNs can be seen through skin or subcutaneous tissue using near infrared camera (Photodynamic Eye®: PDE), and we can easily find the SLNs. However, whenever we observe the fluorescence images, we have to hold the PDE, turn off the operating light, and look at a monitor because fluorescence images cannot be seen directly. Medical imaging projection system (MIPS) is a new device which detects fluorescent emission from the organ and projects their images on the location of the fluorescence emission (Panasonic Connected Solutions Company, Japan). Projected images can be adjusted following the body movement or deformation of the organ. Therefore, MIPS could provide an option for real-time navigation for the SLN biopsy. The aim of this study was to evaluate the clinical utility of the MIPS.
Patients and methods)
Patients with clinically node-negative primary breast cancer underwent the fICG SLN biopsy using MIPS. Primary endpoint was identification rate of the fICG method using MIPS. At first, the study was conducted as an interventional study because the MIPS was the unapproved medical device. After approval of the MIPS, this study was conducted as an observational study. The study protocol was approved by the institutional review board at Kyoto University Hospital. All patients provided informed consent to participate in this study.
Results)
Between March 2016 and May 2017, 39 patients (40 procedures) underwent the fICG method SLN biopsy using MIPS. The median age was 55 years (range 32–74 years), and the median body mass index was 20.4 kg/m2 (range 17.7–27.7 kg/m2). About half had tumor stage T1 (58%) and 8 (20.0%) had DCIS. 8 procedures (20%) were performed after preoperative systemic therapy (PST). As MIPS itself can illuminate the operating field, SLN biopsy using MIPS was successfully performed without operating light in all procedures. At least one SLN was detected using MIPS for all procedures and the identification rate was 100% (95% CI: 91–100%). Median number of SLNs detected by MIPS was 3 (range 1–9) for all procedures, and 3 (range 2–8) for procedures after PST. Two pathologically positive SLNs and one SLN which included isolated tumor cells were detected by MIPS. In 25 procedures, RI was also used. 62 of 97 SLNs detected by MIPS (64%) were also detected by RI. However, no SLNs were detected only by RI.
Conclusions)
Although we still may not be able to avoid RI method because 25/40 (62.5%) procedures required the combined use of RI method, the fICG methods SLN biopsy using MIPS, which showed comparable identification rate of SLN with the conventional methods, could be useful tool with a view of allowing us to perform a real-time navigation surgery.
Acknowledgements)
This study was supported by Acceleration Transformative research for Medical innovation, Japan Agency for Medical Research and Development (AMED).
Citation Format: Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Sakita-Kawaguchi N, Nakayama Y, Okuda T, Nishino H, Seo S, Hatano E, Toi M. Real-time navigation for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD2-07.
Collapse
Affiliation(s)
- M Takada
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - M Takeuchi
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - E Suzuki
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - F Sato
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - Y Matsumoto
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - M Torii
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - N Sakita-Kawaguchi
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - Y Nakayama
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - T Okuda
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - H Nishino
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - S Seo
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - E Hatano
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan; Hyogo College of Medicine, Hyogo, Japan
| |
Collapse
|
18
|
Matsumoto Y, Asao Y, Yoshikawa A, Sekiguchi H, Takada M, Furu M, Saito S, Kataoka M, Abe H, Yagi T, Togashi K, Toi M. Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. Sci Rep 2018; 8:786. [PMID: 29335512 PMCID: PMC5768743 DOI: 10.1038/s41598-018-19161-z] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 12/18/2017] [Indexed: 11/22/2022] Open
Abstract
We analysed the vascular morphology of the palm using a photoacoustic tomography (PAT) instrument with a hemispherical detector array. The three-dimensional (3D) morphology of blood vessels was determined noninvasively. Overall, 12 females and 11 males were recruited as healthy volunteers. Their ages were distributed almost evenly from 22 to 59 years. In all cases, many vascular networks were observed just beneath the skin and were determined to be veins anatomically. To analyse the major arteries, the layer containing the subcutaneous venous network was removed from the image. The analysis focused on the common and proper palmar digital arteries. We used the curvature of these arteries as a parameter to analyse their morphologies. There was no significant difference in the curvature between genders when comparing the subjects as a whole. The blood vessel curvature increased with age. Good agreement was found between the 3D numerical analysis results and the subjective evaluation of the two-dimensional (2D) projection image. The PAT system enabled visualization of the 3D features of blood vessels in the palm and noninvasive analysis of arterial tortuousness.
Collapse
Affiliation(s)
- Y Matsumoto
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
| | - Y Asao
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
- Japan Science and Technology Agency, ImPACT Program, Cabinet Office, K's Gobancho, 7, Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan
| | - A Yoshikawa
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - H Sekiguchi
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - M Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - M Furu
- Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - S Saito
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - M Kataoka
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - H Abe
- Medical Imaging System Development Center, Canon Inc., 3-30-2 Shimomaruko, Ohta-ku, Tokyo, 146-8501, Japan
| | - T Yagi
- Japan Science and Technology Agency, ImPACT Program, Cabinet Office, K's Gobancho, 7, Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan
| | - K Togashi
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| | - M Toi
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan
| |
Collapse
|
19
|
Takada M, Nishida K, Gondo Y, Kikuchi-Hayakawa H, Ishikawa H, Suda K, Kawai M, Hoshi R, Kuwano Y, Miyazaki K, Rokutan K. Beneficial effects of Lactobacillus casei strain Shirota on academic stress-induced sleep disturbance in healthy adults: a double-blind, randomised, placebo-controlled trial. Benef Microbes 2017; 8:153-162. [PMID: 28443383 DOI: 10.3920/bm2016.0150] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The present study examined whether Lactobacillus casei strain Shirota (LcS) improves sleep quality under psychological stress. A double-blind, placebo-controlled trial was conducted in healthy 4th year medical students exposed to academic examination stress. The trial was repeated over two consecutive years in different groups of students, and the data were pooled. For 8 weeks prior to and 3 weeks after a national standardised examination, a total of 48 and 46 subjects received a daily dose of 100 ml of LcS-fermented milk or non-fermented placebo milk, respectively. Study measures included subjective anxiety, overnight single-channel electroencephalography (EEG) recordings, and the Oguri-Shirakawa-Azumi (OSA) sleep inventory scores of subjective sleep quality. Total OSA scores were significantly lower than baseline on the day before the exam and recovered after the exam, indicating a stress-induced decline in sleep quality. There was a significant positive effect of LcS treatment on OSA factors for sleepiness on rising and sleep length. Sleep latency measured by EEG lengthened as the exam approached in the placebo group but was significantly suppressed in the LcS group. The percentage of stage 3 non-REM (N3) sleep decreased in the placebo group as the exam approached, whereas it was maintained in the LcS group throughout the trial. Delta power during the first sleep cycle, measured as an index of sleep intensity, increased as the exam approached in the LcS group and was significantly higher than in the placebo group. These findings suggest that daily consumption of LcS may help to maintain sleep quality during a period of increasing stress. The observed retention of N3 sleep and increased delta power in the LcS group may have contributed to higher perceived sleep satisfaction.
Collapse
Affiliation(s)
- M Takada
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K Nishida
- 2 Department of Pathophysiology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto, Tokushima, Tokushima 770-8503, Japan
| | - Y Gondo
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - H Kikuchi-Hayakawa
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - H Ishikawa
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K Suda
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - M Kawai
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - R Hoshi
- 3 Faculty of Research and Development, Yakult Honsha Co., Ltd., 1-1-19 Higashi-Shimbashi, Minato, Tokyo 105-8660, Japan
| | - Y Kuwano
- 2 Department of Pathophysiology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto, Tokushima, Tokushima 770-8503, Japan
| | - K Miyazaki
- 1 Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K Rokutan
- 2 Department of Pathophysiology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto, Tokushima, Tokushima 770-8503, Japan
| |
Collapse
|
20
|
Kimura K, Inoue K, Kuroiwa Y, Tanaka F, Takada M. Propagated but topologically distributed forebrain neurons expressing alpha-synuclein in aged macaques. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Thaiwong T, Sirivisoot S, Takada M, Yuzbasiyan-Gurkan V, Kiupel M. Gain-of-function mutation inPTPN11in histiocytic sarcomas of Bernese Mountain Dogs. Vet Comp Oncol 2017; 16:220-228. [DOI: 10.1111/vco.12357] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 08/25/2017] [Accepted: 08/28/2017] [Indexed: 01/09/2023]
Affiliation(s)
- T. Thaiwong
- Veterinary Diagnostic Laboratory; Michigan State University; Lansing Michigan
| | - S. Sirivisoot
- Veterinary Diagnostic Laboratory; Michigan State University; Lansing Michigan
- Department of Pathology, Faculty of Veterinary Sciences; Chulalongkorn University; Bangkok Thailand
| | - M. Takada
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine; Michigan State University; East Lansing Michigan
- Comparative Medicine and Integrative Biology Program, College of Veterinary Medicine; Michigan State University; East Lansing Michigan
| | - V. Yuzbasiyan-Gurkan
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine; Michigan State University; East Lansing Michigan
- Comparative Medicine and Integrative Biology Program, College of Veterinary Medicine; Michigan State University; East Lansing Michigan
| | - M. Kiupel
- Veterinary Diagnostic Laboratory; Michigan State University; Lansing Michigan
- Comparative Medicine and Integrative Biology Program, College of Veterinary Medicine; Michigan State University; East Lansing Michigan
- Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine; Michigan State University; East Lansing Michigan
| |
Collapse
|
22
|
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Abstract P4-21-24: Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background)
The addition of trastuzumab to standard neoadjuvant chemotherapy (NAC) doubles the pathological complete response (pCR) rate in patients with HER2-positive primary breast cancer. Patients who achieved pCR after NAC with trastuzumab showed a better prognosis compared to those without pCR. However, it is still difficult to predict the likelihood of recurrence after surgery at an individual patient-level. The aim of this study was to develop a mathematical model to predict disease-free survival (DFS) events such as recurrence for patients treated with NAC and trastuzumab. Because brain metastasis (BM) often occurs in HER2-positive cancer patients and it is a particular event for those, we planned to develop a specific model for BM as well.
Patients and Methods)
Data of 776 HER2-positive primary breast cancer patients from the multicenter cohort study (JBCRG-C03) were used in the analysis. All patients had received NAC plus trastuzumab between 2001 and 2010. Two prediction models using a machine learning method (alternating decision tree algorithm) were developed using age, body-mass index, menopausal status, clinical stage, histological type, ER/PgR status, histological/nuclear grade, type of surgery, pathological response, adjuvant radiation therapy, and adjuvant hormonal therapy. The model A (DFS) predicted the probability of any disease recurrence, death by any cause, or secondary malignancy within 5 years after starting treatment. The model B (BM) predicted the probability of occurrence of BM within the 5 years. First, bias-controlled virtual datasets were generated for the training of the models using a resampling method. Second, the models were optimized by cross-validation (CV). Finally, the developed models were validated using the original dataset. The area under the receiver operating characteristics curve (AUC) was calculated to assess the discrimination ability of the models.
Results)
The DFS and BM event was observed in 118 and 30 patients, respectively. The AUC values for the model A and model B were 0.833 (95% CI, 0.798–0.868, P < 0.001) and 0.927 (95% CI, 0.905–0.949, P < 0.001), respectively. The sensitivity and specificity at the cut-off value of 50% were 72.0% and 78.4% for the model A, and 100% and 83.7% for the model B, respectively. Patients predicted as “low-risk” by the model A showed a significantly better 5-year DFS rate than “high-risk” patients (91.2% vs 53.8%, P < 0.001). Patients predicted as “low-risk” by the model B showed a significantly better 5-year BM-free survival rate than “high-risk” patients (100% vs 76.1%, P < 0.001). The discrimination ability of these models were maintained for both ER/PgR-positive and ER/PgR-negative subgroups, and also for both pCR and non-pCR subgroups.
Conclusions)
Our models showed high accuracy for predicting DFS events and BM in HER2-positive primary breast cancer patients treated with NAC and trastuzumab. These two models would help to realize accurate prediction of DFS events and to optimize the postoperative surveillance plan. The identification of high-risk patients for recurrence including BM may be useful for selecting a patient-subpopulation who requires new therapeutic approach.
Citation Format: Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-24.
Collapse
Affiliation(s)
- M Takada
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - M Sugimoto
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - N Masuda
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - H Iwata
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - K Kuroi
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - H Yamashiro
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - S Ohno
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - H Ishiguro
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - T Inamoto
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan; Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan; Osaka National Hospital, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan; Tenri Hospital, Tenri, Japan; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| |
Collapse
|
23
|
Toi M, Asao Y, Takada M, Kataoka M, Endo T, Kawashima M, Yamaga I, Nakayama Y, Tokiwa M, Fakhrejahani E, Torii M, Kawaguchi-Sakita N, Kanao S, Matsumoto Y, Yagi T, Sakurai T, Togashi K, Shiina T. Abstract P4-01-10: Development of photoacoustic vascular imaging system for breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-01-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Tumor angiogenesis and hypoxia are associated with breast cancer growth and metastasis. Photoacoustic (PA) tomography is an optical imaging technology that visualizes distribution and oxygenation status of hemoglobin with high spatial resolution. Initially we developed a photoacoustic mammography (PAM) having a flat-shaped scanning detector that could detect breast tumors. Nevertheless, the flat-shaped detector array has the drawback of a limited view. Here we developed a novel PAM system with a hemispherical-shaped detector array (HDA), which enables us to identify microvasculatures non-invasively and allow the collection of nearly spatially isotropic three-dimensional reconstructed image of blood vessels. This non-invasive vascular imaging system may be able to characterize tumor angiogenesis and analyze the status of microcirculation. The aim of this study was to analyze the imaging findings of tumor-related vasculature in breast cancer patients.
Patients and method:
A PAM system with HDA has been generated in a cooperation project between Canon Inc., Japan, and Kyoto University. Twenty-two primary breast cancer patients, including 5 patients with non-invasive cancer and 17 patients with invasive cancer, diagnosed between December 2014 and December 2015 underwent the PAM imaging analysis. We also applied the breast deformation algorithm from the breast shape in a MRI image to that in a PA image in order to create a fusion image of the two modalities for the analysis. Features of peri- and intra-tumoral vasculature, and their oxygenation status were evaluated. The study protocol was approved by the institutional review board at Kyoto University Hospital (UMIN000012251). All patients provided informed consent to participate in this study.
Results:
The abnormal peri-tumoral vasculature was detected in 86% of all non-invasive and invasive disease cases. In invasive cancer cases, most tumor-related blood vessels were centripetally directed toward the tumor, and 93% of centripetal blood vessels appeared to be disrupted or rapidly narrowed at the tumor boundary. The centripetal blood vessel structure was frequently observed in invasive cancer compared with non-invasive cancer (61% vs 35%). PA images before and after preoperative chemotherapy were obtained in one case, where intra-tumoral blood vessels became finer after chemotherapy, reflecting normalization of intra-tumoral microcirculation induced by chemotherapy.
Conclusions:
A PAM system with HDA has provided a high-resolution vascular images of primary breast cancers. The morphological differences of peri-tumoral vasculature were observed between invasive disease and non-invasive disease. These results suggest the potential of PA imaging as a non-invasive tool to analyze tumor vasculature of human breast cancers and maybe be helpful for breast cancer diagnosis.
(Acknowledgements)
This work was partially supported by the Innovative Techno-Hub for Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
Citation Format: Toi M, Asao Y, Takada M, Kataoka M, Endo T, Kawashima M, Yamaga I, Nakayama Y, Tokiwa M, Fakhrejahani E, Torii M, Kawaguchi-Sakita N, Kanao S, Matsumoto Y, Yagi T, Sakurai T, Togashi K, Shiina T. Development of photoacoustic vascular imaging system for breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-01-10.
Collapse
Affiliation(s)
- M Toi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - Y Asao
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - M Takada
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - M Kataoka
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - T Endo
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - M Kawashima
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - I Yamaga
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - Y Nakayama
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - M Tokiwa
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - E Fakhrejahani
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - M Torii
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - N Kawaguchi-Sakita
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - S Kanao
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - Y Matsumoto
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - T Yagi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - T Sakurai
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - K Togashi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| | - T Shiina
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Medical Imaging System Development Center, Canon Inc., Tokyo, Japan
| |
Collapse
|
24
|
Toi M, Asao Y, Matsumoto Y, Sekiguchi H, Yoshikawa A, Takada M, Kataoka M, Endo T, Kawaguchi-Sakita N, Kawashima M, Fakhrejahani E, Kanao S, Yamaga I, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Togashi K, Shiina T. Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array. Sci Rep 2017; 7:41970. [PMID: 28169313 PMCID: PMC5294462 DOI: 10.1038/srep41970] [Citation(s) in RCA: 147] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 12/28/2016] [Indexed: 12/19/2022] Open
Abstract
Noninvasive measurement of the distribution and oxygenation state of hemoglobin (Hb) inside the tissue is strongly required to analyze the tumor-associated vasculatures. We developed a photoacoustic imaging (PAI) system with a hemispherical-shaped detector array (HDA). Here, we show that PAI system with HDA revealed finer vasculature, more detailed blood-vessel branching structures, and more detailed morphological vessel characteristics compared with MRI by the use of breast shape deformation of MRI to PAI and their fused image. Morphologically abnormal peritumoral blood vessel features, including centripetal photoacoustic signals and disruption or narrowing of vessel signals, were observed and intratumoral signals were detected by PAI in breast cancer tissues as a result of the clinical study of 22 malignant cases. Interestingly, it was also possible to analyze anticancer treatment-driven changes in vascular morphological features and function, such as improvement of intratumoral blood perfusion and relevant changes in intravascular hemoglobin saturation of oxygen. This clinical study indicated that PAI appears to be a promising tool for noninvasive analysis of human blood vessels and may contribute to improve cancer diagnosis.
Collapse
Affiliation(s)
- M. Toi
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - Y. Asao
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
- Medical Imaging System Development Center, Canon Inc., 3-30-2 Shimomaruko, Ohta-ku, Tokyo 146-8501, Japan
| | - Y. Matsumoto
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - H. Sekiguchi
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 6068507, Japan
| | - A. Yoshikawa
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - M. Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - M. Kataoka
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 6068507, Japan
| | - T. Endo
- Medical Imaging System Development Center, Canon Inc., 3-30-2 Shimomaruko, Ohta-ku, Tokyo 146-8501, Japan
| | - N. Kawaguchi-Sakita
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - M. Kawashima
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - E. Fakhrejahani
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - S. Kanao
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 6068507, Japan
| | - I. Yamaga
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - Y. Nakayama
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - M. Tokiwa
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - M. Torii
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - T. Yagi
- Medical Imaging System Development Center, Canon Inc., 3-30-2 Shimomaruko, Ohta-ku, Tokyo 146-8501, Japan
| | - T. Sakurai
- Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| | - K. Togashi
- Medical Imaging System Development Center, Canon Inc., 3-30-2 Shimomaruko, Ohta-ku, Tokyo 146-8501, Japan
| | - T. Shiina
- Department of Human Health Science, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho Sakyo-ku, Kyoto 606-8507, Japan
| |
Collapse
|
25
|
Yamaguchi A, Ishiguro H, Torii M, Takada M, Suzuki E, Takeuchi M, Sato F, Toi M. 69P Cisplatin based preoperative chemotherapy regimens for basal-like breast cancer potentially improve prognosis even in patients without pCR: A retrospective analysis from a single-institution. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00229-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
26
|
Yamaguchi A, Ishiguro H, Torii M, Takada M, Suzuki E, Takeuchi M, Sato F, Toi M. 69P Cisplatin based preoperative chemotherapy regimens for basal-like breast cancer potentially improve prognosis even in patients without pCR: A retrospective analysis from a single-institution. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw575.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol 2016; 27:1818-28. [PMID: 27436850 PMCID: PMC5035783 DOI: 10.1093/annonc/mdw263] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 06/24/2016] [Accepted: 06/28/2016] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Chemotherapy (CT) combined with radiotherapy is the standard treatment of 'limited-stage' small-cell lung cancer. However, controversy persists over the optimal timing of thoracic radiotherapy and CT. MATERIALS AND METHODS We carried out a meta-analysis of individual patient data in randomized trials comparing earlier versus later radiotherapy, or shorter versus longer radiotherapy duration, as defined in each trial. We combined the results from trials using the stratified log-rank test to calculate pooled hazard ratios (HRs). The primary outcome was overall survival. RESULTS Twelve trials with 2668 patients were eligible. Data from nine trials comprising 2305 patients were available for analysis. The median follow-up was 10 years. When all trials were analysed together, 'earlier or shorter' versus 'later or longer' thoracic radiotherapy did not affect overall survival. However, the HR for overall survival was significantly in favour of 'earlier or shorter' radiotherapy among trials with a similar proportion of patients who were compliant with CT (defined as having received 100% or more of the planned CT cycles) in both arms (HR 0.79, 95% CI 0.69-0.91), and in favour of 'later or longer' radiotherapy among trials with different rates of CT compliance (HR 1.19, 1.05-1.34, interaction test, P < 0.0001). The absolute gain between 'earlier or shorter' versus 'later or longer' thoracic radiotherapy in 5-year overall survival for similar and for different CT compliance trials was 7.7% (95% CI 2.6-12.8%) and -2.2% (-5.8% to 1.4%), respectively. However, 'earlier or shorter' thoracic radiotherapy was associated with a higher incidence of severe acute oesophagitis than 'later or longer' radiotherapy. CONCLUSION 'Earlier or shorter' delivery of thoracic radiotherapy with planned CT significantly improves 5-year overall survival at the expense of more acute toxicity, especially oesophagitis.
Collapse
Affiliation(s)
- D De Ruysscher
- Department of Radiation Oncology (MAASTRO Clinic), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands Department of Oncology, Experimental Radiation Oncology, KU Leuven, Leuven, Belgium
| | - B Lueza
- Department of Biostatistics and Epidemiology and "Ligue Nationale Contre le Cancer" meta-analysis platform, Gustave Roussy, Villejuif, France CESP, INSERM U1018, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - C Le Péchoux
- Department of Oncology and radiation therapy, Gustave Roussy, Villejuif Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - D H Johnson
- UT Southwestern University School of Medicine, Dallas, USA
| | - M O'Brien
- EORTC Data Center, Brussels, Belgium
| | - N Murray
- British Columbia Cancer Agency, Vancouver, Canada
| | - S Spiro
- University College London Hospitals, London, UK
| | - X Wang
- Alliance Data and Statistical Center, Duke University, Durham, USA
| | - M Takada
- Osaka Prefectural Habikino Hospital, Osaka, Japan
| | - B Lebeau
- Hôpital St Antoine, Paris, France
| | - W Blackstock
- Wake Forest University School of Medicine, Winston-Salem, USA
| | - D Skarlos
- Second Department of Medical Oncology, Metropolitan Hospital N. Faliro, Athens, Greece
| | - P Baas
- The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - H Choy
- Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA
| | - A Price
- NHS Lothian and University of Edinburgh, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
| | - L Seymour
- NCIC Clinical Trials Group and Queen's University, Kingston, Canada
| | - R Arriagada
- Gustave Roussy, Villejuif, France Karolinska Institutet, Stockholm, Sweden
| | - J-P Pignon
- Department of Biostatistics and Epidemiology and "Ligue Nationale Contre le Cancer" meta-analysis platform, Gustave Roussy, Villejuif, France CESP, INSERM U1018, Université Paris-Sud, Université Paris-Saclay, Villejuif
| |
Collapse
|
28
|
Nandy M, Sarkar PK, Sanami T, Takada M, Shibata T. Neutron emission and dose distribution from natural carbon irradiated with a 12 MeV amu -1 12C 5+ ion beam. J Radiol Prot 2016; 36:456-473. [PMID: 27355162 DOI: 10.1088/0952-4746/36/3/456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Measured neutron energy distribution emitted from a thick stopping target of natural carbon at 0°, 30°, 60° and 90° from nuclear reactions caused by 12 MeV amu-1 incident 12C5+ ions were converted to energy differential and total neutron absorbed dose as well as ambient dose equivalent H *(10) using the fluence-to-dose conversion coefficients provided by the ICRP. Theoretical estimates were obtained using the Monte Carlo nuclear reaction model code PACE and a few existing empirical formulations for comparison. Results from the PACE code showed an underestimation of the high-energy part of energy differential dose distributions at forward angles whereas the empirical formulation by Clapier and Zaidins (1983 Nucl. Instrum. Methods 217 489-94) approximated the energy integrated angular distribution of H *(10) satisfactorily. Using the measured data, the neutron doses received by some vital human organs were estimated for anterior-posterior exposure. The estimated energy-averaged quality factors were found to vary for different organs from about 7 to about 13. Emitted neutrons having energies above 20 MeV were found to contribute about 20% of the total dose at 0° while at 90° the contribution was reduced to about 2%.
Collapse
Affiliation(s)
- Maitreyee Nandy
- Saha Institute of Nuclear Physics, 1/AF, Bidhannagar, Kolkata 700064, West Bengal, India
| | | | | | | | | |
Collapse
|
29
|
Takada M, Nunomiya T, Nakamura T, Matsumoto T, Masuda A. CHARACTERIZATION OF A THIN SILICON SENSOR FOR ACTIVE NEUTRON PERSONAL DOSEMETERS. Radiat Prot Dosimetry 2016; 170:213-217. [PMID: 27150515 DOI: 10.1093/rpd/ncw118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Accepted: 04/15/2016] [Indexed: 06/05/2023]
Abstract
A thin silicon sensor has been developed for active neutron personal dosemeters for use by aircrews and first responders. This thin silicon sensor is not affected by the funneling effect, which causes detection of cosmic protons and over-response to cosmic neutrons. There are several advantages to the thin silicon sensor: a decrease in sensitivity to gamma rays, an improvement of the energy detection limit for neutrons down to 0.8 MeV and an increase in the sensitivity to fast neutrons. Neutron response functions were experimentally obtained using 2.5 and 5 MeV monoenergy neutron beams and a (252)Cf neutron source. Simulation results using the Monte Carlo N-Particle transport code agree quite well with the experimental ones when an energy deposition region shaped like a circular truncated cone is used in place of a cylindrical region.
Collapse
Affiliation(s)
- M Takada
- National Defense Academy, Yokosuka 239-8686, Japan
| | - T Nunomiya
- Fuji Electric Co., Ltd., Hino, Tokyo 191-8502, Japan
| | - T Nakamura
- Fuji Electric Co., Ltd., Hino, Tokyo 191-8502, Japan Cyclotron and Radioisotope Center, Tohoku University, Sendai 980-8579, Japan
| | - T Matsumoto
- National Institute of Advanced Industrial Science and Technology, Tsukuba 305-8568, Japan
| | - A Masuda
- National Institute of Advanced Industrial Science and Technology, Tsukuba 305-8568, Japan
| |
Collapse
|
30
|
Takada M, Nishida K, Kataoka-Kato A, Gondo Y, Ishikawa H, Suda K, Kawai M, Hoshi R, Watanabe O, Igarashi T, Kuwano Y, Miyazaki K, Rokutan K. Probiotic Lactobacillus casei strain Shirota relieves stress-associated symptoms by modulating the gut-brain interaction in human and animal models. Neurogastroenterol Motil 2016; 28:1027-36. [PMID: 26896291 DOI: 10.1111/nmo.12804] [Citation(s) in RCA: 149] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Accepted: 01/24/2016] [Indexed: 02/08/2023]
Abstract
BACKGROUND This study aimed to examine the effects of Lactobacillus casei strain Shirota (LcS) on gut-brain interactions under stressful conditions. METHODS Three double-blind, placebo-controlled trials were conducted to examine the effects of LcS on psychological and physiological stress responses in healthy medical students under academic examination stress. Subjects received LcS-fermented milk or placebo daily for 8 weeks prior to taking a national standardized examination. Subjective anxiety scores, salivary cortisol levels, and the presence of physical symptoms during the intervention were pooled and analyzed. In the animal study, rats were given feed with or without LcS for 2 weeks, then submitted to water avoidance stress (WAS). Plasma corticosterone concentration and the expression of cFos and corticotropin releasing factor (CRF) in the paraventricular nucleus (PVN) were measured immediately after WAS. In an electrophysiological study, gastric vagal afferent nerve activity was monitored after intragastric administration of LcS to urethane-anesthetized rats. KEY RESULTS Academic stress-induced increases in salivary cortisol levels and the incidence rate of physical symptoms were significantly suppressed in the LcS group compared with the placebo group. In rats pretreated with LcS, WAS-induced increases in plasma corticosterone were significantly suppressed, and the number of CRF-expressing cells in the PVN was reduced. Intragastric administration of LcS stimulated gastric vagal afferent activity in a dose-dependent manner. CONCLUSIONS & INFERENCES These findings suggest that LcS may prevent hypersecretion of cortisol and physical symptoms under stressful conditions, possibly through vagal afferent signaling to the brain and reduced stress reactivity in the PVN.
Collapse
Affiliation(s)
- M Takada
- Yakult Central Institute, Tokyo, Japan
| | - K Nishida
- Department of Pathophysiology, Tokushima University Graduate School of Medicine, Tokushima, Japan
| | | | - Y Gondo
- Yakult Central Institute, Tokyo, Japan
| | | | - K Suda
- Yakult Central Institute, Tokyo, Japan
| | - M Kawai
- Yakult Central Institute, Tokyo, Japan
| | - R Hoshi
- Faculty of Research and Development, Yakult Honsha Co., Ltd., Tokyo, Japan
| | - O Watanabe
- Faculty of Research and Development, Yakult Honsha Co., Ltd., Tokyo, Japan
| | - T Igarashi
- Faculty of Research and Development, Yakult Honsha Co., Ltd., Tokyo, Japan
| | - Y Kuwano
- Department of Pathophysiology, Tokushima University Graduate School of Medicine, Tokushima, Japan
| | | | - K Rokutan
- Department of Pathophysiology, Tokushima University Graduate School of Medicine, Tokushima, Japan
| |
Collapse
|
31
|
Kato-Kataoka A, Nishida K, Takada M, Suda K, Kawai M, Shimizu K, Kushiro A, Hoshi R, Watanabe O, Igarashi T, Miyazaki K, Kuwano Y, Rokutan K. Fermented milk containing Lactobacillus casei strain Shirota prevents the onset of physical symptoms in medical students under academic examination stress. Benef Microbes 2016; 7:153-6. [DOI: 10.3920/bm2015.0100] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
This pilot study investigated the effects of the probiotic Lactobacillus casei strain Shirota (LcS) on psychological, physiological, and physical stress responses in medical students undertaking an authorised nationwide examination for promotion. In a double-blind, placebo-controlled trial, 24 and 23 healthy medical students consumed a fermented milk containing LcS and a placebo milk, respectively, once a day for 8 weeks until the day before the examination. Psychophysical state, salivary cortisol, faecal serotonin, and plasma L-tryptophan were analysed on 5 different sampling days (8 weeks before, 2 weeks before, 1 day before, immediately after, and 2 weeks after the examination). Physical symptoms were also recorded in a diary by subjects during the intervention period for 8 weeks. In association with a significant elevation of anxiety at 1 day before the examination, salivary cortisol and plasma L-tryptophan levels were significantly increased in only the placebo group (P<0.05). Two weeks after the examination, the LcS group had significantly higher faecal serotonin levels (P<0.05) than the placebo group. Moreover, the rate of subjects experiencing common abdominal and cold symptoms and total number of days experiencing these physical symptoms per subject were significantly lower in the LcS group than in the placebo group during the pre-examination period at 5-6 weeks (each P<0.05) and 7-8 weeks (each P<0.01) during the intervention period. Our results suggest that the daily consumption of fermented milk containing LcS may exert beneficial effects preventing the onset of physical symptoms in healthy subjects exposed to stressful situations.
Collapse
Affiliation(s)
- A. Kato-Kataoka
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K. Nishida
- Department of Pathophysiology, Tokushima University Graduate School of Medicine, 3-18-5 Kuramoto, Tokushima, Tokushima 770-8503, Japan
| | - M. Takada
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K. Suda
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - M. Kawai
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - K. Shimizu
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - A. Kushiro
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - R. Hoshi
- Faculty of Research and Development, Yakult Honsya Co., Ltd., 1-1-19 Higashi-Shimbashi, Minato, Tokyo 105-8660, Japan
| | - O. Watanabe
- Faculty of Research and Development, Yakult Honsya Co., Ltd., 1-1-19 Higashi-Shimbashi, Minato, Tokyo 105-8660, Japan
| | - T. Igarashi
- Faculty of Research and Development, Yakult Honsya Co., Ltd., 1-1-19 Higashi-Shimbashi, Minato, Tokyo 105-8660, Japan
| | - K. Miyazaki
- Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan
| | - Y. Kuwano
- Department of Pathophysiology, Tokushima University Graduate School of Medicine, 3-18-5 Kuramoto, Tokushima, Tokushima 770-8503, Japan
| | - K. Rokutan
- Department of Pathophysiology, Tokushima University Graduate School of Medicine, 3-18-5 Kuramoto, Tokushima, Tokushima 770-8503, Japan
| |
Collapse
|
32
|
Takada M, Kawashima M, Kataoka M, Kanao S, Yamaga I, Torii M, Tokiwa M, Fakhrejahani E, Sakurai T, Asao Y, Haga H, Shiina T, Togashi K, Toi M. Abstract P4-03-03: Detection of the tumor vasculature and the hypoxic status of breast lesions using second-generation photoacoustic mammography: An exploratory study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor angiogenesis and hypoxia are associated with breast cancer growth and metastasis. Photoacoustic mammography (PAM) non-invasively visualizes hemoglobin distribution inside the breast by detecting thermoelastic waves from hemoglobin generated by the irradiation of a near-infrared laser pulse. Oxygen saturation (SO2) can be calculated using photoacoustic (PA) signals obtained by two laser pulses of different wavelengths. We further improved the spatial resolution of PAM by approximately 1 mm and enhanced detectability by using a high-sensitivity detector. This new PAM technique can obtain both PAM images and ultrasonography (US) images simultaneously. The aim of this study was to explore the clinical usefulness of this PAM technique.
Patients and methods: Women who had breast lesions were eligible for this study. The participants' lesions were measured using the new PAM technique before they began treatment. The PAM images were evaluated by 5 physicians. First, the lesions were identified using only the PAM images. Second, we used US or contrast-enhanced magnetic resonance images (CE-MRI) to identify the locations of the lesions. Next, we evaluated the photoacoustic (PA) signals based on their locations. Peri-tumoral PA signals were defined as linear signals that congregated in the peri-tumoral area, boundary PA signals were defined as peri-tumoral signals that were disrupted at the lesion's boundaries, and intra-tumoral PA signals were defined as any significant PA signals inside the tumor. SO2 was illustrated using a color scale. The study protocol was approved by the institutional review board at Kyoto University Hospital, Japan (UMIN000007464).
Results: PAM was performed on 48 breast lesions in 45 patients, including 36 invasive carcinoma lesions, 8 ductal carcinoma in situ (DCIS) lesions, and 4 benign lesions. Evaluations of PA signals according to the locations of the lesion, with confirmation from US or CE-MRI, were successfully performed for 38 lesions. Peri-tumoral PA signals were detected in 33 lesions (87%), disrupted boundary PA signals were detected in 30 lesions (79%), and intra-tumoral PA signals were detected in 25 lesions (66%). The detection rates for peri-tumoral, boundary and intra-tumoral PA signals were 94%, 87%, and 65% for invasive carcinoma, and 60%, 40%, and 80% for DCIS, respectively. Intra-tumoral PA signals tended to be weaker than peri-tumoral PA signals in invasive carcinoma lesions, and they often displayed a spotty rather than a linear shape. Intra-tumoral PA signals were observed to have lower SO2 levels than peri-tumoral PA signals in 95% of invasive carcinoma lesions and in 75% of DCIS lesions. Although peri-tumoral and boundary PA signals were also detected in a 38-mm fibroadenoma, the intra-tumoral PA signals displayed a diffuse pattern.
Conclusions: We demonstrated that high spatial resolution and use in combination with US and CE-MRI facilitate the region-specific evaluation of PAM imaging. PAM could become a useful tool for the evaluation of the hypoxic status of tumors by enhancing its sensitivity.
Citation Format: Takada M, Kawashima M, Kataoka M, Kanao S, Yamaga I, Torii M, Tokiwa M, Fakhrejahani E, Sakurai T, Asao Y, Haga H, Shiina T, Togashi K, Toi M. Detection of the tumor vasculature and the hypoxic status of breast lesions using second-generation photoacoustic mammography: An exploratory study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-03-03.
Collapse
Affiliation(s)
- M Takada
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Kawashima
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Kataoka
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - S Kanao
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - I Yamaga
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Torii
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Tokiwa
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - E Fakhrejahani
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Sakurai
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Y Asao
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - H Haga
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Shiina
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - K Togashi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Toi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Canon Inc., Tokyo, Japan; Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
33
|
Nishimura S, Takashima T, Kawajiri H, Kashiwagi S, Noda S, Tokunaga S, Tei S, Yamagata S, Sunami T, Tezuka K, Ikeda K, Mizuyama Y, Ogawa Y, Onoda N, Nishimori T, Ishikawa T, Kudo S, Takada M, Hirakawa K. 1859 Clinical effects of prior chemotherapy on eribulin: Update and subgroup analysis of phase 2 multicenter single arm study of eribulin mesylate as first-line therapy for HER2 negative locally advanced or metastatic breast cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30809-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Kondo Y, Sawa R, Ebina A, Takada M, Fujii H, Okuyama Y, Tanikawa Y, Soke K, Tanaka S, Shirakata M, Ono R. Influence of habitual physical activity in late pregnancy on the duration of labor. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.2055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 2015:265-75. [PMID: 6667250 DOI: 10.1159/000408467] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
From analysis of the clinical and laboratory findings in the DIC patients collected by JRDC, diagnostic criteria for the diagnosis of DIC are proposed. The characteristics of the criteria are as follows: (1) a scoring system is adopted; (2) as the tests for scoring, PT, plasma Fbg level, serum FDP level, and platelet count are used; (3) different scores are given according to the grade of change in the results of the tests; (4) bleeding and clinical signs indicating organ dysfunction due to DIC are included in the scoring system; and (5) recognition of the well-known etiological factors of DIC is also scored.
Collapse
|
36
|
Gonmori H, Maekawa T, Kobayashi N, Tanaka H, Tsukada H, Takada M, Andou K. The role of tissue thromboplastin in the development of DIC accompanying neoplastic diseases. Bibl Haematol 2015:23-39. [PMID: 6667248 DOI: 10.1159/000408444] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Procoagulant activity of gastric cancer tissues and leukocytes obtained from various types of leukemia have been studied with special reference to TTP. The following results were obtained. Homogenates of APL leukocytes and gastric cancer tissues contained strong procoagulant activities, most of which have been identified as TTP since the activities were neutralized by a specific antibody against purified human placenta TTP, inactivated by the removal of phospholipid with heptane-butanol mixture, and inactivated by the addition of phospholipase C. The delipidated homogenates regained procoagulant activities by relipidation procedures. These results also confirmed that TTP from APL leukocytes and gastric cancer tissues have the same lipoprotein properties as those of TTP in normal tissues. Though slight proteolytic activity and fibrinolytic activity were demonstrated in the homogenate of gastric cancer tissues, it was noted that the TTP activity was different from these two activities by partial purification of TTP from gastric cancer tissues. The TTP activity of 9 homogenates of gastric cancer tissues was 301 +/- 289 (mean +/- SD) units per mg protein, being higher in homogenates of mucinous adenocarcinoma and signet-ring cell carcinoma than in those of tubular and poorly differentiated adenocarcinoma. The mean TTP activity of leukocyte homogenates from 14 patients with APL and one out of 4 patients with CML in blastic crisis was 81 +/- 76 units/10(7) cells. The TTP activity of the homogenates of leukocytes from 7 out of 18 patients with AML and another patient with CML in blastic crisis ranged from one to six units/10(7) cells with a mean of 3.3 +/- 1.2. The TTP activity of leukocyte homogenates from the other 11 cases of AML, two cases of CML in blastic crisis, 6 cases of CML, and one case each of ALL and CLL were less than one unit/10(7) cells. In leukemic patients, all cases with a value of more than 202 for the product of units of TTP activity per 10(7) cells and differential count (%) of leukemic cells in the bone marrow smear (MU value) were accompanied by DIC. The MU value of leukemic patients correlated well to the plasma fibrinogen and serum FDP levels. All patients with a MU value of more than 277 died of DIC when a sufficient amount of heparin was not administered. On the other hand, no DIC developed in any of the patients with a MU value of less than 90.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
37
|
Fakhrejahani E, Torii M, Yamaga I, Asao Y, Kitai T, Kataoka M, Kanao S, Takada M, Shiina T, Toi M. P051 Photoacoustic imaging of breast cancer and histological markers of angiogenesis. Breast 2015. [DOI: 10.1016/s0960-9776(15)70101-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
38
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat 2014; 145:143-53. [PMID: 24682674 DOI: 10.1007/s10549-014-2907-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 03/04/2014] [Indexed: 10/25/2022]
Abstract
We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using multivariate analyses. The 3-year DFS rate was 87 % [95 % confidence interval (CI) 85-90]. The pathologic complete response (pCR: ypT0/is + ypN0) rate was 51 %. The pCR rate was higher in the ER/PgR-negative patients than in the ER/PgR-positive patients (64 vs. 36 %, P < 0.001). Patients with pCR showed a higher DFS rate than patients without pCR (93 vs. 82 %, P < 0.001). Multivariate analysis revealed three independent predictors for poorer DFS: advanced nodal stage [hazard ratio (HR) 2.63, 95 % CI 1.36-5.21, P = 0.004 for cN2-3 vs. cN0], histological/nuclear grade 3 (HR 1.81, 95 % CI 1.15-2.91, P = 0.011), and non-pCR (HR 1.98, 95 % CI 1.22-3.24, P = 0.005). In the ER/PgR-negative dataset, non-pCR (HR 2.63, 95 % CI 1.43-4.90, P = 0.002) and clinical tumor stage (HR 2.20, 95 % CI 1.16-4.20, P = 0.017 for cT3-4 vs. cT1-2) were independent predictors for DFS, and in the ER/PgR-positive dataset, histological grade of 3 (HR 3.09, 95 % CI 1.48-6.62, P = 0.003), clinical nodal stage (HR 4.26, 95 % CI 1.53-13.14, P = 0.005 for cN2-3 vs. cN0), and young age (HR 2.40, 95 % CI 1.12-4.94, P = 0.026 for ≤40 vs. >40) were negative predictors for DFS. Strict pCR (ypT0 + ypN0) was an independent predictor for DFS in both the ER/PgR-negative and -positive datasets (HR 2.66, 95 % CI 1.31-5.97, P = 0.006 and HR 3.86, 95 % CI 1.13-24.21, P = 0.029, respectively). These results may help assure a more accurate prognosis and personalized treatment for HER2-positive breast cancer patients.
Collapse
Affiliation(s)
- M Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Takeshita H, Nagai T, Sagi M, Chiba S, Kanno S, Takada M, Mukai T. Forensic identification using multiple lot numbers of an implanted device. Med Sci Law 2014; 54:51-53. [PMID: 24052003 DOI: 10.1177/0025802413498860] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
We report a case in which identification of a deceased individual was established using multiple lot numbers printed on a body implantable device. Autopsy of an unknown woman revealed an intramedullary nail inserted within her right femur. The device manufacturer was identified from the configuration of the intramedullary nail, and the "use history" was traced from lot numbers printed on the device's multiple parts. The deceased individual was thus identified as a woman who had attempted suicide by jumping from a height about a year previously and had been transported to a hospital and undergone surgery that included implantation of the intramedullary nail. The main factor contributing to the rapid identification was the manufacturer's and distributor's record of the use history (traceability) of the product, because of their accountability for purposes of quality control. A second contributing factor was multiple lot numbers, resulting in extremely low probability of the same combination of lot numbers being present in multiple individuals. This case confirmed the utility of multiple lot numbers of body implantable devices in forensic identification.
Collapse
Affiliation(s)
- H Takeshita
- Department of Legal Medicine, St. Marianna University School of Medicine, Japan
| | | | | | | | | | | | | |
Collapse
|
40
|
Fakhrejahani E, Torii M, Yamaga I, Asao Y, Kitai T, Kataoka M, Kanao S, Takada M, Shiina T, Toi M. Abstract P2-03-09: Tissue hemoglobin oxygen saturation measured by photoacoustic mammography correlates with microvasculature properties assessed by histological image analysis, a preliminary study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-03-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Photoacoustic mammography (PAM) is a new optical imaging technology with the potential of imaging tumor vasculature in breast cancer.The technique is applicable to the measurement of hemoglobin oxygen saturation (SO2).We have previously published an initial clinical result using a prototype machine (Canon Inc.,Tokyo, Japan) in breast cancer. We have also presented the morphological characteristics of tumor vessels analyzed by automated image processing during AACR annual meeting 2013. Here, we report the oxygenation data obtained by PAM in relation with histological assessment of tumor vasculature and hypoxia.
Methods: Forty-four breast lesions were evaluated by PAM in this IRB approved prospective study at Kyoto University Hospital, Japan. PAM evaluation was performed on both breasts whenever possible.SO2 was calculated in region of interest after the radiologist confirmed the signal was associated with the tumor location in MRI images. For the normal breast, signals obtained at the same depth of the tumor, were selected. Eighty-one histological sections from 20 available invasive carcinoma tissues at the time of this analysis were selected for immunohistochemical assessment of hypoxia by anti -carbonic anhydrase IX (CA IX) and tumor vasculature image analysis using anti-CD31. Five 0.5 mm2 area of each cancer and 3 area of normal mammary tissue associated with the same lesion were randomly selected from different sections. Total vascular area in each square was calculated by using Image Pro-Plus 7.0 software (Media Cybernetics, USA). Tumor-to-normal vascular area ratio (T/N VA) was calculated for each lesion as an index for tumor blood supply.
Results: Patients’ age ranged from 36 to 83 years old. Tumor associated signals were detected by PAM in 18 out of 20 lesions for which tissues were available for histological examination. SO2 in tumor was calculated 70.6% ±13.2 and 83.3% ±10.7 in the normal counterpart. While T/N VA ranged between 0.11 to 1.14, it was almost 3 times lower in lesions with CA IX positive cytoplasmic membrane staining (0.21 vs 0.7, p-value = 0.021 Mann-Whitney Test). Normalized tumor SO2 (tumor SO2/normal counterpart SO2) was significantly lower in the group with lower T/N VA (0.9 vs. 0.8,p-value = 0.045, Student T-test). To better evaluate the accuracy of PAM measurement in calculating SO2,3780 tumor-associated and 2835 normal microvessels were analyzed by image analysis software. Tumor associated vessels had significantly smaller area (p-value<0.001) and vessels with irregular lumens were more frequent in tumor (76.5% vs 19.6% p-value <0.001) compatible with lower SO2 in tumor areas.
Conclusion: Although the future result of our ongoing clinical studies of PAM measurement in breast cancer patients are more than necessary, the strong correlation between histological evaluation of hypoxia and angiogenesis with PAM measurement of oxygenation shows the promising prospective for clinical application of this new technology in breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-03-09.
Collapse
Affiliation(s)
- E Fakhrejahani
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - M Torii
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - I Yamaga
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - Y Asao
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - T Kitai
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - M Kataoka
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - S Kanao
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - M Takada
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - T Shiina
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| | - M Toi
- Kyoto University, Kyoto, Japan; Kishiwada City Hospital, Kishiwada, Osaka, Japan
| |
Collapse
|
41
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
Addition of trastuzumab to neoadjuvant chemotherapy (NAC) improved pathologic complete response (pCR) rate in HER2-positive breast cancer. Although recent trials have shown favorable prognosis with NAC plus trastuzumab, clinicopathological factors to predict the outcome have not been fully understood. The aim of this study was to investigate the survival after NAC with trastuzumab and to explore the predictive factors.
PATIENTS AND METHODS:
This is a multicenter retrospective observational study. Patients with HER2-positive primary breast cancer treated with NAC plus trastuzumab from 2001 to 2010 were identified from the institutional database. Primary end point was disease-free survival (DFS). pCR was defined as ypT0/is+ypN0. Kaplan-Meier method was used to estimate DFS. Logistic regression and proportional hazard analysis were used to identify clinicopathological factors to predict pCR and DFS, respectively.
RESULTS:
733 patients were included in the analysis (whole dataset). 425 were ER/PgR-negative (HR- dataset) and 306 were ER/PgR-positive (HR+ dataset). Radiation therapy was performed in 90% of lumpectomy and 31% of mastectomy. Hormonal therapy was performed in 84% of HR+ dataset. pCR rate was 45% in whole dataset, 60% in HR- dataset, and 34% in HR+ dataset. Table 1 showed the result of multivariate analysis for pCR in whole dataset. When HR+ and HR- dataset were analyzed separately, no definitive predictors for pCR were identified in multivariate analysis. Although the patients with pCR showed a significantly favorable prognosis than those without pCR at 3 years DFS, in whole dataset (93% vs 83%, p<0.0001) and HR- dataset (94% vs 80%, p<0.0001), there was no significant difference in HR+ dataset (89% vs 86%, p = 0.10). Different predictors were selected for DFS when multivariate analysis was conducted separately between HR- and HR+ dataset (Table 2).
CONCLUSIONS:
In this observational study, we clarified predictors for pCR and DFS in HER2-positive patients treated with neoadjuvant trastuzumab containing therapy based on tumor subtype. Our results may help us to predict the prognosis more precisely and to simulate the disease course.
Table 1) Multivariate logistic regression analysis for pCR in whole datasetFactorsOR95%CIp-valuePost- vs Pre-menopause1.50(1.05-2.15)0.026*cT1-2 vs cT3-41.72(1.16-2.59)0.008*ER/PgR-negative vs ER/PgR-positive3.32(2.30-4.82)<0.0001*Grade 3 vs 1-21.28(0.89-1.84)0.183
Table 2) Multivariate proportional hazard analysis for DFSFactors†HR95%CIp-valueWhole dataset Pre- vs Post-menopause1.61(1.04-2.52)0.033*cN2-3 vs cN03.06(1.58-6.24)0.001*cN1 vs cN02.26(1.23-4.41)0.007*Grade 3 vs 1-21.87(1.20-2.97)0.006*non-pCR vs pCR1.90(1.18-3.13)0.008*HR- dataset Pre- vs Post-menopause1.70(1.01-2.85)0.046*cT3-4 vs cT1-21.86(1.09-3.17)0.024*non-pCR vs pCR3.28(1.90-5.87)<0.0001*HR+ dataset cN2-3 vs cN05.01(1.79-16.19)0.002*cN1 vs cN03.50(1.40-10.61)0.006*Grade 3 vs 1-22.95(1.52-5.87)0.001*†Only factors with statistical significance
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-20.
Collapse
Affiliation(s)
- M Takada
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Ishiguro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Nagai
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohtani
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Kawabata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Yanagita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Hozumi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - C Shimizu
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Takao
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Sato
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Kosaka
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Sagara
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Iwata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohno
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - K Kuroi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Masuda
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Yamashiro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Sugimoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Kondo
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Naito
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Sasano
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - T Inamoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Morita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| |
Collapse
|
42
|
Al Anid H, Lewis BJ, Bennett LGI, Takada M, Duldig M. Aircrew radiation dose estimates during recent solar particle events and the effect of particle anisotropy. Radiat Prot Dosimetry 2013; 158:355-367. [PMID: 24084521 DOI: 10.1093/rpd/nct234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
A model was developed using a Monte-Carlo radiation transport code, MCNPX, to estimate the additional radiation exposure to aircrew members during solar particle events. The model transports an extrapolated particle spectrum based on satellite measurements through the atmosphere to aircraft altitudes. This code produces the estimated flux at a specific altitude where radiation dose conversion coefficients are applied to convert the particle flux into effective and ambient dose-equivalent rates. A cut-off rigidity model accounts for the shielding effects of the Earth's magnetic field. Comparisons were made between the model predictions and actual flight measurements taken with various types of instruments used to measure the mixed radiation field during ground level enhancements (GLEs) 60 and 65. An anisotropy analysis that uses neutron monitor responses and the pitch angle distribution of energetic solar particles was used to identify particle anisotropy for a solar event in December 2006. In anticipation of future commercial use, a computer code has been developed to implement the radiation dose assessment model for routine analysis.
Collapse
Affiliation(s)
- H Al Anid
- Department of Chemistry and Chemical Engineering, Royal Military College of Canada, PO Box 17000, Kingston, ON, Canada K7 K 7B4
| | | | | | | | | |
Collapse
|
43
|
Takada M, Fukusaki M, Terao Y, Yamashita K, Inadomi C, Sumikawa K. Comparative efficacy of ropivacaine and bupivacaine for epidural block in outpatients with degenerative spinal disease and low back pain. ACTA ACUST UNITED AC 2013. [DOI: 10.1163/1568569054729481] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
44
|
Fakhrejahani E, Asao Y, Yamaga I, Torii M, Takada M, Kitai T, Sugie T, Toi M. Evaluation of Oxygenation in Breast Cancers by Photoacoustic Mammography: Clinical and Histological Comparison. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt144.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Fakhrejahani E, Asao Y, Yamaga I, Torii M, Takada M, Kitai T, Sugie T, Toi M. AOSP46 EVALUATION OF BREAST TISSUE MICROVASCULATURE WITH DIGITAL PATHOLOGY AND IMAGE ANALYSIS BRINGS NEW INSIGHTS INTO TUMOUR ANGIOGENESIS ASSESSMENT. Eur J Cancer 2013. [DOI: 10.1016/s0959-8049(13)70056-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Takada M, Saji S, Honma N, Masuda N, Yamamoto Y, Kuroi K, Yamashita H, Ohno S, Aogi K, Ueno T, Toi M. Abstract P3-06-18: Increase of serum androgen and its metabolites in postmenopausal primary breast cancer patients with disease progression during neo-adjuvant exemestane treatment; JFMC 34–0601 TR. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-06-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: We reported a positive correlation between body mass index (BMI) and clinical response to neo-adjuvant hormonal therapy (NAH) with steroidal aromatase inhibitor, exemestane, in post-menopausal breast cancer patients (Takada M et al. Breast 2012). Here, we examined the relationship between serum concentrations of sex steroids and BMI, and explored their predictive value for clinical response.
PATIENTS AND METHODS: Among the 116 post-menopausal patients enrolled in the JFMC 34–0601 clinical trial of 24 weeks (wks) of NAH with exemestane, serums from 60 patients at pre-treatment, at 4wks and end of the treatment (24wks) were subjected to this study. Estradiol (E2), estrone (E1), dehydroepiandrosterone (DHEA), androstenedione (A-dione), 5-androstene-3β, 17β-diol (Aenediol), 5α-androstane-3β, 17β-diol (Aanediol) were measured using LC-MS/MS analysis and E1- sulfate (E1S) was by RIA.
RESULTS: There were no significant correlations between pre-treatment concentrations of sex steroids and BMI, except for moderate correlation of E2 and BMI (p = 0.004). In multivariate analysis, E1 was an independent predictive factor for objective response [odds 6.0, 95% confidence interval (CI) 1.5 — 34.6, p = 0.011], as well as BMI. All of the estrogens decreased to under-detection levels (0.5 for E1 and E2, 5 pg/assay for E1S) at 4 wks of treatment, and maintained through to the end of treatment in almost all patients independently of clinical response. The geometric mean percentage changes in androgens after NAH were: DHEA −0.2% (95%CI −15.3% — +17.6%) for patients without progressive disease (non-PD) and +44.8% (95%CI +22.1% — +71.8%) for patients with progressive disease (PD); A-dione −2.3% (95%CI −17.3% — +15.4%) for non-PD and +45.6% (95%CI +28.3% — +65.3%) for PD; Aenediol −11.5% (95%CI −20.6% — −1.4%) for non-PD and +24.9% (95%CI +1.9% — +53.0%) for PD; Aanediol +21.3% (95%CI −5.5% — +55.8%) for non-PD and +56.3% (95%CI +5.3% — +132.0%) for PD, respectively. The changes in the concentrations of both DHEA and A-dione in patients with PD were statistically significant (p = 0.008 and p = 0.002, respectively). In all of the PD patients, the serum concentrations of DHEA and A-dione were increased after NAH.
CONCLUSION: Pretreatment serum concentration of E1 was an independent predictive factor for clinical response to NAH with exemestane. Measurement of dynamics of the serum androgen concentrations might be helpful for monitoring treatment response, and mechanism of increase of androgens has a value for further investigation. Our results should be validated using a larger dataset. (UMIN ID; C000000345)
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-06-18.
Collapse
Affiliation(s)
- M Takada
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - S Saji
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - N Honma
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - N Masuda
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - Y Yamamoto
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - K Kuroi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - H Yamashita
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - S Ohno
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - K Aogi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - T Ueno
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - M Toi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Canwithdrcer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| |
Collapse
|
47
|
Goto N, Matsuda Y, Takada M, Yamamoto T, Tsujita M, Hiramitsu T, Nanmoku K, Watarai Y, Katayama A, Kobayashi T, Uchida K. Long-Term Outcome in Kidney Transplant Recipients with HTLV-1 Carriers. Transplantation 2012. [DOI: 10.1097/00007890-201211271-00670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Ohno A, Hirashima T, Kubo A, Masuda N, Takada M, Fujiwara H, Yasumitsu T, Kikui M, Fukuoka M, Nakagawa K. p53 status and prognosis in stage I-IIIa non-small cell lung cancer. Int J Oncol 2012; 10:521-8. [PMID: 21533407 DOI: 10.3892/ijo.10.3.521] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
To investigate the role of p53 abnormalities in predicting the survival of patients with non-small cell lung cancer (NSCLC), polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and immunohistochemical analyses were performed on 74 and 67 tumor samples, respectively, from patients with pathological stage I-IIIa NSCLC. An abnormally migrating SSCP band was observed in 21 of 74 (28%) tumor specimens. DNA sequence analysis revealed 23 intragenic mutations including 3 small deletions and 20 point mutations. Immunohistochemical analysis using the DO-7 monoclonal antibody showed abnormal expression of p53 in 27 of 67 (40%) patients. The concordance rate between immunohistochemical and PCRSSCP analyses was 73% (49/67) in this study. Univariate and multivariate analyses demonstrated that abnormal expression of p53 may be associated with prolonged survival (p=0.0997 and 0.0099, respectively). In contrast, no relationship was observed between p53 mutation and overall survival (0.6968). These results suggest that p53 status and the survival outcome changes between immunohistochemical and mutational analyses in stage I-IIIa NSCLC.
Collapse
Affiliation(s)
- A Ohno
- KINKI UNIV,SCH MED,DEPT INTERNAL MED 4,OSAKA,OSAKA 589,JAPAN. GIFU UNIV,SCH MED,DEPT INTERNAL MED 2,GIFU 500,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT INTERNAL MED,HABIKINO,OSAKA 583,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT SURG,HABIKINO,OSAKA 583,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT PATHOL,HABIKINO,OSAKA 583,JAPAN
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Omachi N, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M, Nishie K. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32323-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
50
|
Saji S, Takada M, Honma N, Masuda N, Yamamoto Y, Kuroi K, Yamashita H, Ohno S, Ueno T, Toi M. Serum Concentration of Estrone (E1), not Estradiol (E2), is the Independent Predictive Factor of Response to Neo-Adjuvant Exemestane Treatment in Postmenopausal Breast Cancer Patients: JFMC 34-0601 TR. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32840-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|